Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bone Biologics Corporation
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
August 02, 2024
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
BBLGW
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
June 20, 2024
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
BBLGW
Bone Biologics Announces Closing of $2.0 Million Public Offering
March 06, 2024
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics Announces Pricing of $2.0 Million Public Offering
March 04, 2024
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics Reports Progress With NB1 Clinical Program
March 01, 2024
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
January 11, 2024
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
BBLGW
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
January 10, 2024
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
BBLGW
Bone Biologics Announces 1-for-8 Reverse Stock Split
December 18, 2023
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
BBLGW
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 20, 2023
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 16, 2023
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics Prices $5.0 Million Underwritten Public Offering
June 14, 2023
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics Effects 1-for-30 Reverse Stock Split
June 06, 2023
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
April 11, 2023
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
January 26, 2023
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics CEO Issues Letter to Stockholders
October 25, 2022
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering
October 12, 2022
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering
October 07, 2022
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
March 23, 2022
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference
January 05, 2022
From
Bone Biologics Corporation
Via
Business Wire
Tickers
BBLG
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.